PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 20555322-5 2010 Vascular invasion was disturbed in the rapamycin group, there was a significant reduction in osteoclast cells near the chondro-osseus junction, and there was lower VEGF protein and mRNA expression in the terminal chondrocytes of the growth cartilage. Sirolimus 39-48 vascular endothelial growth factor A Homo sapiens 164-168 20106729-4 2010 VEGF(165) was constantly secreted by all cultured tumor cells in an mTOR-dependent manner, as it was inhibited by the mTOR inhibitor rapamycin. Sirolimus 133-142 vascular endothelial growth factor A Homo sapiens 0-4 20070623-7 2010 We show that the inflammatory immune response was significantly altered in TSC patients as compared with controls and sirolimus potently affected both inflammatory cytokine production and vascular endothelial growth factor levels in these patients. Sirolimus 118-127 vascular endothelial growth factor A Homo sapiens 188-222 20179227-1 2010 Everolimus, an orally administered rapamycin analog, has recently been approved by the U.S. Food and Drug Administration for treatment of renal cell carcinoma (RCC) refractory to inhibitors of vascular endothelial growth factor (VEGF) receptor signaling. Sirolimus 35-44 vascular endothelial growth factor A Homo sapiens 193-227 19634141-7 2010 While rapamycin was effective at reducing NF1-MPNST proliferation and angiogenesis, with decreased CyclinD1 and VEGF respectively, there was no increase in tumor apoptosis. Sirolimus 6-15 vascular endothelial growth factor A Homo sapiens 112-116 19919613-8 2010 VEGF was suppressed thoroughly in two-month use of sirolimus. Sirolimus 51-60 vascular endothelial growth factor A Homo sapiens 0-4 19919613-12 2010 Suppressed expression of VEGF, p-Akt, and p-mTOR was the major event of signaling modification through the long-term use of sirolimus. Sirolimus 124-133 vascular endothelial growth factor A Homo sapiens 25-29 19797172-8 2009 Quantitative polymerase chain reaction in human aortic endothelial cells (HAECs) revealed that sirolimus (but not paclitaxel) inhibited RSG-induced vascular endothelial growth factor transcription. Sirolimus 95-104 vascular endothelial growth factor A Homo sapiens 148-182 19336014-2 2009 Dissection of the molecular pathways that regulate proliferation, apoptosis, and angiogenesis has led to the development of targeted therapies such as the receptor tyrosine kinase inhibitors sunitinib and sorafenib, the anti-vascular endothelial growth factor antibody bevacizumab, and a class of rapamycin analogues including everolimus and temsirolimus. Sirolimus 297-306 vascular endothelial growth factor A Homo sapiens 225-259 19789339-11 2009 Rapamycin treatment did not markedly suppress VEGF in tumors and synergized only in tumor lines where VEGF was dramatically inhibited by CP751,871. Sirolimus 0-9 vascular endothelial growth factor A Homo sapiens 102-106 19789339-12 2009 These data suggest a model in which blockade of IGF-1R suppresses tumor-derived VEGF to a level where rapamycin can effectively suppress the response in vascular endothelial cells. Sirolimus 102-111 vascular endothelial growth factor A Homo sapiens 80-84 19347904-6 2009 In contrast, treatment with rapamycin for 24 h reduced overall translation by approximately 45% and affected the translation of mRNAs with complex 5" UTRs, specifically VEGF and HIF1alpha. Sirolimus 28-37 vascular endothelial growth factor A Homo sapiens 169-173 19260835-0 2009 ID2-VEGF-related pathways in the pathogenesis of Kaposi"s sarcoma: a link disrupted by rapamycin. Sirolimus 87-96 vascular endothelial growth factor A Homo sapiens 4-8 19002496-9 2009 Quantitative RT-PCR showed that sirolimus down-regulated the mRNA expression of VEGF and HIF-1a, but not of bFGF, and TGF-b in MHCC97H cells. Sirolimus 32-41 vascular endothelial growth factor A Homo sapiens 80-84 19002496-10 2009 Furthermore, western blot analysis confirmed that sirolimus also decreased expression of HIF-1a at protein level, in parallel with the down-regulation of the levels of VEGF protein excretion in a time-dependent manner as compared to untreated control cells following anoxia. Sirolimus 50-59 vascular endothelial growth factor A Homo sapiens 168-172 19002496-11 2009 CONCLUSIONS: The immunosuppressive macrolide sirolimus prevents the growth and metastatic progression of HCC, and suppresses VEGF synthesis and secretion by downregulating HIF-1a expression. Sirolimus 45-54 vascular endothelial growth factor A Homo sapiens 125-129 18703055-5 2008 Rapamycin did not induce EC apoptosis, but reduced both VEGF-production in RPE and the responsiveness of ECs to stimulation. Sirolimus 0-9 vascular endothelial growth factor A Homo sapiens 56-60 19081609-10 2009 Rapamycin decreased hypoxia-induced synthesis of vascular endothelial growth factor. Sirolimus 0-9 vascular endothelial growth factor A Homo sapiens 49-83 19018001-4 2008 We found that rapamycin, which blocks mTORC1 and mTORC2 signaling, inhibited sCD40L-mediated transactivation of VEGF. Sirolimus 14-23 vascular endothelial growth factor A Homo sapiens 112-116 18927120-5 2009 We also evidenced that vascular endothelial growth factor (VEGF) synthesis and Akt phosphorylation were decreased by sirolimus addition. Sirolimus 117-126 vascular endothelial growth factor A Homo sapiens 23-57 18927120-5 2009 We also evidenced that vascular endothelial growth factor (VEGF) synthesis and Akt phosphorylation were decreased by sirolimus addition. Sirolimus 117-126 vascular endothelial growth factor A Homo sapiens 59-63 19074906-8 2008 Furthermore, rapamycin not only drastically inhibited CXCL16-induced PCa cell invasion and growth but reduced secretion of IL-8 or VEGF levels and inhibited expression of other CXCR6 targets including CD44 and matrix metalloproteinase 3 in PCa cells. Sirolimus 13-22 vascular endothelial growth factor A Homo sapiens 131-135 18930332-9 2008 Rapamycin inhibits phosphorylation of p70 S6 kinase and 4E-BP-1, downstream targets of mTOR, and decreases VEGF. Sirolimus 0-9 vascular endothelial growth factor A Homo sapiens 107-111 25983921-3 2008 Also, vascular endothelial growth factor (VEGF) staining in the biopsy samples resolved following rapamycin therapy. Sirolimus 98-107 vascular endothelial growth factor A Homo sapiens 6-40 25983921-3 2008 Also, vascular endothelial growth factor (VEGF) staining in the biopsy samples resolved following rapamycin therapy. Sirolimus 98-107 vascular endothelial growth factor A Homo sapiens 42-46 18454167-3 2008 Angiogenesis and VEGF are thought to play a crucial role in fracture healing and as osteoporotic and traumatic fractures are common complications in immunosuppressed, organ transplantation patients, we conducted this study to analyze the effect of rapamycin treatment on bone repair. Sirolimus 248-257 vascular endothelial growth factor A Homo sapiens 17-21 18278068-6 2008 MYCN siRNA significantly blocked VEGF secretion, irrespective of serum conditions, in MYCN-amplified NB cells; this effect was enhanced when combined with rapamycin, an mTOR inhibitor. Sirolimus 155-164 vascular endothelial growth factor A Homo sapiens 33-37 18490075-7 2008 Reductions in tumor growth by bevacizumab plus rapamycin were associated with inhibition of downstream targets of the mammalian target-of-rapamycin pathway, reductions in vascular endothelial growth factor expression, and tumor microvessel density. Sirolimus 47-56 vascular endothelial growth factor A Homo sapiens 171-205 18490075-8 2008 Potentially additive effects of bevacizumab plus rapamycin included reductions in vascular endothelial growth factor expression, cyclin D1, and cyclin B1. Sirolimus 49-58 vascular endothelial growth factor A Homo sapiens 82-116 17583372-2 2007 Studies have demonstrated that sirolimus acts as a vascular endothelial growth factor inhibitor, providing prospective therapeutic benefits and possible prevention of tuberous sclerosis and Kaposi"s sarcoma. Sirolimus 31-40 vascular endothelial growth factor A Homo sapiens 51-85 18559329-0 2008 Vascular endothelial growth factor protein levels and gene expression in peripheral monocytes after stenting: a randomized comparative study of sirolimus-eluting and bare-metal stents. Sirolimus 144-153 vascular endothelial growth factor A Homo sapiens 0-34 18305085-0 2008 Vascular endothelial growth factor protein levels and gene expression in peripheral monocytes after stenting: a randomized comparative study of sirolimus: eluting and bare metal stents. Sirolimus 144-153 vascular endothelial growth factor A Homo sapiens 0-34 18305085-2 2008 We assessed VEGF serum protein levels and gene expression in peripheral monocytes in relation to in-stent restenosis after implantation of sirolimus-eluting (SES) and bare metal stents (BMS) in a non-blinded, randomized study. Sirolimus 139-148 vascular endothelial growth factor A Homo sapiens 12-16 17968710-0 2007 Sirolimus inhibits human pancreatic carcinoma cell proliferation by a mechanism linked to the targeting of mTOR/HIF-1 alpha/VEGF signaling. Sirolimus 0-9 vascular endothelial growth factor A Homo sapiens 124-128 17553806-8 2007 We find that rapamycin totally blocks vascular endothelial growth factor and Akt-inducible phosophorylation of these transcription factors in endothelial cells. Sirolimus 13-22 vascular endothelial growth factor A Homo sapiens 38-72 17968710-5 2007 Sirolimus is effective in vivo against pancreatic carcinoma and demonstrates that the effect of sirolimus on the inhibition of tumor cell proliferation is associated with the suppression of the mTOR/HIF-1alpha/vascular endothelial growth factor (VEGF) pathway. Sirolimus 0-9 vascular endothelial growth factor A Homo sapiens 210-244 17968710-5 2007 Sirolimus is effective in vivo against pancreatic carcinoma and demonstrates that the effect of sirolimus on the inhibition of tumor cell proliferation is associated with the suppression of the mTOR/HIF-1alpha/vascular endothelial growth factor (VEGF) pathway. Sirolimus 0-9 vascular endothelial growth factor A Homo sapiens 246-250 17968710-5 2007 Sirolimus is effective in vivo against pancreatic carcinoma and demonstrates that the effect of sirolimus on the inhibition of tumor cell proliferation is associated with the suppression of the mTOR/HIF-1alpha/vascular endothelial growth factor (VEGF) pathway. Sirolimus 96-105 vascular endothelial growth factor A Homo sapiens 210-244 17968710-5 2007 Sirolimus is effective in vivo against pancreatic carcinoma and demonstrates that the effect of sirolimus on the inhibition of tumor cell proliferation is associated with the suppression of the mTOR/HIF-1alpha/vascular endothelial growth factor (VEGF) pathway. Sirolimus 96-105 vascular endothelial growth factor A Homo sapiens 246-250 17804674-4 2007 Immunohistochemistry showed that sirolimus attenuated the increased expression of renal vascular endothelial growth factor (VEGF), as well as the expression of VEGF receptors 1 and 2. Sirolimus 33-42 vascular endothelial growth factor A Homo sapiens 88-122 17804674-4 2007 Immunohistochemistry showed that sirolimus attenuated the increased expression of renal vascular endothelial growth factor (VEGF), as well as the expression of VEGF receptors 1 and 2. Sirolimus 33-42 vascular endothelial growth factor A Homo sapiens 124-128 17502379-4 2007 Our work shows that activation of mTOR by Ras homologue enriched in brain (Rheb) overexpression potently enhances the activity of HIF1alpha and vascular endothelial growth factor (VEGF)-A secretion during hypoxia, which is reversed with rapamycin. Sirolimus 237-246 vascular endothelial growth factor A Homo sapiens 144-178 17502379-4 2007 Our work shows that activation of mTOR by Ras homologue enriched in brain (Rheb) overexpression potently enhances the activity of HIF1alpha and vascular endothelial growth factor (VEGF)-A secretion during hypoxia, which is reversed with rapamycin. Sirolimus 237-246 vascular endothelial growth factor A Homo sapiens 180-184 17338432-12 2007 The concomitant use of sirolimus, which inhibits vascular endothelial growth factor, plus gemcitabine may have resulted in TMA. Sirolimus 23-32 vascular endothelial growth factor A Homo sapiens 49-83 17483438-5 2007 Rapamycin, a selective inhibitor of mTOR, reduced VEGF production in rhabdomyosarcoma cells under normoxic conditions and partially suppressed hypoxia-driven increases in VEGF. Sirolimus 0-9 vascular endothelial growth factor A Homo sapiens 50-54 17483438-5 2007 Rapamycin, a selective inhibitor of mTOR, reduced VEGF production in rhabdomyosarcoma cells under normoxic conditions and partially suppressed hypoxia-driven increases in VEGF. Sirolimus 0-9 vascular endothelial growth factor A Homo sapiens 171-175 17386117-2 2007 Sirolimus, an immunosuppressive drug used for kidney transplant, exhibits antiangiogenic activity related to impaired production of VEGF (vascular endothelial growth factor), clinical benefit has been reported in Kaposi"s sarcoma associated with renal graft. Sirolimus 0-9 vascular endothelial growth factor A Homo sapiens 132-136 17386117-2 2007 Sirolimus, an immunosuppressive drug used for kidney transplant, exhibits antiangiogenic activity related to impaired production of VEGF (vascular endothelial growth factor), clinical benefit has been reported in Kaposi"s sarcoma associated with renal graft. Sirolimus 0-9 vascular endothelial growth factor A Homo sapiens 138-172 16778423-8 2006 The thrombosis and withdrawal of sirolimus may have acted as cofactors in the development of KS, favouring the activation of the VEGF/KDR autocrine loop. Sirolimus 33-42 vascular endothelial growth factor A Homo sapiens 129-133 17136757-10 2007 Addition of the inhibitors WP631, mitoxantrone, and Rapamycin to keloid keratinocyte and fibroblast co-cultures, downregulated secreted VEGF expression in a dose-dependent manner, suggesting therapeutic potential for these compounds in the treatment of keloid scars. Sirolimus 52-61 vascular endothelial growth factor A Homo sapiens 136-140 16854316-14 2006 The VEGF protein level in the supernatant of the culture fluid of MHCC97H cells of the RPM group was (890.3 +/- 25.1) pg/ml, significantly lower than that of the control group, (1583.7 +/- 17.3) pg/ml (P = 0.000). Sirolimus 87-90 vascular endothelial growth factor A Homo sapiens 4-8 16981910-7 2006 The expression of angiogenesis-related factors VEGF, alphaVbeta3 integrin and thrombospondin-1 on islet endothelium was altered in the presence of rapamycin. Sirolimus 147-156 vascular endothelial growth factor A Homo sapiens 47-51 15784722-0 2005 Identification of mTOR as a novel bifunctional target in chronic myeloid leukemia: dissection of growth-inhibitory and VEGF-suppressive effects of rapamycin in leukemic cells. Sirolimus 147-156 vascular endothelial growth factor A Homo sapiens 119-123 16162193-0 2005 Sirolimus-induced thrombotic microangiopathy is associated with decreased expression of vascular endothelial growth factor in kidneys. Sirolimus 0-9 vascular endothelial growth factor A Homo sapiens 88-122 16162193-1 2005 The aim of this study was to examine the clinical characteristics, the histological features and the renal expression of vascular endothelial growth factor (VEGF) of five patients with sirolimus-associated thrombotic microangiopathy (TMA). Sirolimus 185-194 vascular endothelial growth factor A Homo sapiens 121-155 16162193-1 2005 The aim of this study was to examine the clinical characteristics, the histological features and the renal expression of vascular endothelial growth factor (VEGF) of five patients with sirolimus-associated thrombotic microangiopathy (TMA). Sirolimus 185-194 vascular endothelial growth factor A Homo sapiens 157-161 16162193-3 2005 We found that renal VEGF expression during sirolimus-induced TMA was significantly lower than VEGF expression in normal transplanted kidneys (p < 0.01). Sirolimus 43-52 vascular endothelial growth factor A Homo sapiens 20-24 16162193-4 2005 Decreased expression of VEGF seems to be a consequence of sirolimus treatment since (i) analysis of two biopsies performed after the switch of sirolimus to calcineurin inhibitor showed reappearance of VEGF expression, (ii) no decreased expression of VEGF was found in five kidneys with classical TMA and, (iii) an increased expression of VEGF was observed in seven kidneys with acute cellular rejection on a sirolimus-free immunosuppressive regimen (p < 0.01). Sirolimus 58-67 vascular endothelial growth factor A Homo sapiens 24-28 16162193-4 2005 Decreased expression of VEGF seems to be a consequence of sirolimus treatment since (i) analysis of two biopsies performed after the switch of sirolimus to calcineurin inhibitor showed reappearance of VEGF expression, (ii) no decreased expression of VEGF was found in five kidneys with classical TMA and, (iii) an increased expression of VEGF was observed in seven kidneys with acute cellular rejection on a sirolimus-free immunosuppressive regimen (p < 0.01). Sirolimus 58-67 vascular endothelial growth factor A Homo sapiens 201-205 16162193-4 2005 Decreased expression of VEGF seems to be a consequence of sirolimus treatment since (i) analysis of two biopsies performed after the switch of sirolimus to calcineurin inhibitor showed reappearance of VEGF expression, (ii) no decreased expression of VEGF was found in five kidneys with classical TMA and, (iii) an increased expression of VEGF was observed in seven kidneys with acute cellular rejection on a sirolimus-free immunosuppressive regimen (p < 0.01). Sirolimus 58-67 vascular endothelial growth factor A Homo sapiens 201-205 16162193-4 2005 Decreased expression of VEGF seems to be a consequence of sirolimus treatment since (i) analysis of two biopsies performed after the switch of sirolimus to calcineurin inhibitor showed reappearance of VEGF expression, (ii) no decreased expression of VEGF was found in five kidneys with classical TMA and, (iii) an increased expression of VEGF was observed in seven kidneys with acute cellular rejection on a sirolimus-free immunosuppressive regimen (p < 0.01). Sirolimus 58-67 vascular endothelial growth factor A Homo sapiens 201-205 16162193-4 2005 Decreased expression of VEGF seems to be a consequence of sirolimus treatment since (i) analysis of two biopsies performed after the switch of sirolimus to calcineurin inhibitor showed reappearance of VEGF expression, (ii) no decreased expression of VEGF was found in five kidneys with classical TMA and, (iii) an increased expression of VEGF was observed in seven kidneys with acute cellular rejection on a sirolimus-free immunosuppressive regimen (p < 0.01). Sirolimus 143-152 vascular endothelial growth factor A Homo sapiens 24-28 16162193-4 2005 Decreased expression of VEGF seems to be a consequence of sirolimus treatment since (i) analysis of two biopsies performed after the switch of sirolimus to calcineurin inhibitor showed reappearance of VEGF expression, (ii) no decreased expression of VEGF was found in five kidneys with classical TMA and, (iii) an increased expression of VEGF was observed in seven kidneys with acute cellular rejection on a sirolimus-free immunosuppressive regimen (p < 0.01). Sirolimus 143-152 vascular endothelial growth factor A Homo sapiens 24-28 16162193-5 2005 The potential role of sirolimus-induced downregulation of VEGF as a predisposing factor to the development of TMA is discussed. Sirolimus 22-31 vascular endothelial growth factor A Homo sapiens 58-62 15671443-0 2005 Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGF. Sirolimus 0-9 vascular endothelial growth factor A Homo sapiens 81-85 15671443-6 2005 In human umbilical vein endothelial cells vascular endothelial growth factor (VEGF)-induced tissue factor expression was strongly enhanced by rapamycin. Sirolimus 142-151 vascular endothelial growth factor A Homo sapiens 42-76 15671443-6 2005 In human umbilical vein endothelial cells vascular endothelial growth factor (VEGF)-induced tissue factor expression was strongly enhanced by rapamycin. Sirolimus 142-151 vascular endothelial growth factor A Homo sapiens 78-82 15671443-9 2005 The circumstance that VEGF is up-regulated in most tumors may explain the remarkable selectivity of tumor vessel thrombosis under rapamycin therapy. Sirolimus 130-139 vascular endothelial growth factor A Homo sapiens 22-26 15784722-2 2005 We have recently shown that rapamycin down-regulates expression of vascular endothelial growth factor (VEGF), a mediator of leukemia-associated angiogenesis, in primary CML cells. Sirolimus 28-37 vascular endothelial growth factor A Homo sapiens 67-101 15784722-2 2005 We have recently shown that rapamycin down-regulates expression of vascular endothelial growth factor (VEGF), a mediator of leukemia-associated angiogenesis, in primary CML cells. Sirolimus 28-37 vascular endothelial growth factor A Homo sapiens 103-107 15784722-3 2005 In the present study, we analyzed growth-inhibitory in vitro and in vivo effects of rapamycin on primary CML cells and asked whether rapamycin-induced suppression of VEGF in leukemic cells is related to growth inhibition. Sirolimus 133-142 vascular endothelial growth factor A Homo sapiens 166-170 15520200-9 2004 Indeed, VEGF-induced proliferation of HUVECs was sensitive to rapamycin, an inhibitor of p70 S6K activation. Sirolimus 62-71 vascular endothelial growth factor A Homo sapiens 8-12 15848592-3 2005 Sirolimus may reduce t-r-VEGF synthesis and inhibit PI3K-p70S6 kinase of endothelial cells. Sirolimus 0-9 vascular endothelial growth factor A Homo sapiens 25-29 15770593-5 2005 Rapamycin is a potent immunosuppressor with antifibrotic action in renal allografts and has a demonstrated anti-VEGF effect. Sirolimus 0-9 vascular endothelial growth factor A Homo sapiens 112-116 12957289-7 2003 In contrast, Rapamycin only partially downregulates VEGF in this setting, implying an mTOR-independent link between TSC2 loss and VEGF. Sirolimus 13-22 vascular endothelial growth factor A Homo sapiens 52-56 15050414-12 2004 Our results also indicated that the mTOR/FRAP inhibitor, rapamycin, inhibited 4-OHE2-induced HIF-1alpha and VEGF-A expression. Sirolimus 57-66 vascular endothelial growth factor A Homo sapiens 108-114 14500340-5 2003 Rapamycin, a mTOR inhibitor, reduced the production of VEGF by Tsc1- and Tsc2-null fibroblasts to normal levels. Sirolimus 0-9 vascular endothelial growth factor A Homo sapiens 55-59 15064712-7 2004 Inhibition of the VEGF receptor and PKB/Akt-downstream PIK-related mTOR-kinase by rapamycin also neutralized the VEGF-protective effect in an PKB/Akt gene expression-independent way but results in proteolysis-dependent reduction of PKB/Akt protein stability. Sirolimus 82-91 vascular endothelial growth factor A Homo sapiens 18-22 15064712-7 2004 Inhibition of the VEGF receptor and PKB/Akt-downstream PIK-related mTOR-kinase by rapamycin also neutralized the VEGF-protective effect in an PKB/Akt gene expression-independent way but results in proteolysis-dependent reduction of PKB/Akt protein stability. Sirolimus 82-91 vascular endothelial growth factor A Homo sapiens 113-117 34936813-8 2022 mTOR inhibitor rapamycin significantly suppressed the elevation of IL-6, IL-8, and VEGF stimulated by 7-KC. Sirolimus 15-24 vascular endothelial growth factor A Homo sapiens 83-87 12393646-7 2002 BCR/ABL-induced VEGF gene expression was counteracted by the phosphoinositide 3-kinase (PI3-kinase) inhibitor LY294002 and rapamycin, an antagonist of mammalian target of rapamycin (mTOR), but not by inhibition of the mitogen-activated protein kinase pathway. Sirolimus 123-132 vascular endothelial growth factor A Homo sapiens 16-20 12089560-4 2002 Introduction of this activator into human cells allowed expression of the chromosomal VEGF gene to be induced by a small-molecule dimerizer compound consisting of a nonimmunosuppressive rapamycin analog. Sirolimus 186-195 vascular endothelial growth factor A Homo sapiens 86-90 10048588-5 1999 Selective inhibition of ERK, PI 3-kinase, and p70 S6 kinase with the inhibitors PD098059, LY294002, and rapamycin, respectively, inhibited VEGF-stimulated HUVEC proliferation. Sirolimus 104-113 vascular endothelial growth factor A Homo sapiens 139-143 10749120-4 2000 LY294002 and rapamycin also inhibit growth factor- and mitogen-induced secretion of vascular endothelial growth factor, the product of a known HIF-1 target gene, thus linking the PI3K/PTEN/AKT/FRAP pathway, HIF-1, and tumor angiogenesis. Sirolimus 13-22 vascular endothelial growth factor A Homo sapiens 84-118 34936813-0 2022 Mammalian Target of Rapamycin Inhibitor Rapamycin Alleviates 7-Ketocholesterol Induced Inflammatory Responses and Vascular Endothelial Growth Factor Elevation by Regulating MAPK Pathway in Human Retinal Pigment Epithelium Cells. Sirolimus 40-49 vascular endothelial growth factor A Homo sapiens 114-148 33479328-6 2021 Treatment with rapamycin inhibited the diabetes-induced VEGF and GFAP increases. Sirolimus 15-24 vascular endothelial growth factor A Homo sapiens 56-60 35300418-11 2022 In agreement with these results, reduced expression of vascular endothelial growth factor (VEGF) mRNA was observed in MGCs with Rapamycin, whereas pigment epithelium-derived factor (PEDF) mRNA levels significantly increased in MGCs incubated with Resveratrol. Sirolimus 128-137 vascular endothelial growth factor A Homo sapiens 55-89 35300418-11 2022 In agreement with these results, reduced expression of vascular endothelial growth factor (VEGF) mRNA was observed in MGCs with Rapamycin, whereas pigment epithelium-derived factor (PEDF) mRNA levels significantly increased in MGCs incubated with Resveratrol. Sirolimus 128-137 vascular endothelial growth factor A Homo sapiens 91-95 32885169-5 2020 Based on this, we demonstrate that our rapamycin-VEGF hierarchical coating impressively promoted the competitive growth of endothelial cells over smooth muscle cells (ratio of EC/SMC~25) while relieving the adverse impact of rapamycin to ECs. Sirolimus 39-48 vascular endothelial growth factor A Homo sapiens 49-53 33114161-5 2020 Treatment with a combination Gem and Rapa was much more effective than that of either single agent with respect to reducing cell viability, cell invasion, cell migration, and vascular endothelial growth factor production in vitro. Sirolimus 37-41 vascular endothelial growth factor A Homo sapiens 175-209 32885169-5 2020 Based on this, we demonstrate that our rapamycin-VEGF hierarchical coating impressively promoted the competitive growth of endothelial cells over smooth muscle cells (ratio of EC/SMC~25) while relieving the adverse impact of rapamycin to ECs. Sirolimus 225-234 vascular endothelial growth factor A Homo sapiens 49-53 32885169-6 2020 We further conducted the real-time loading of VEGF on stents and demonstrate that the hierarchical combination of rapamycin and VEGF showed remarkable endothelium regeneration while maintaining a very low level of in-stent restenosis. Sirolimus 114-123 vascular endothelial growth factor A Homo sapiens 46-50 30846465-9 2019 Baseline serum vascular endothelial growth factor (VEGF)-D >600 pg mL-1 identified subgroups of patients who were more likely to decline on placebo and respond to treatment with sirolimus. Sirolimus 181-190 vascular endothelial growth factor A Homo sapiens 15-49 31990892-3 2020 Sirolimus, which inhibits mammalian target of rapamycin, a regulator of cell growth and vascular endothelial growth factor expression, has successfully treated systemic vascular malformations. Sirolimus 0-9 vascular endothelial growth factor A Homo sapiens 88-122 31408438-9 2019 Administration of sirolimus significantly attenuated CD8+ T cell activation and decreased VEGF-A levels. Sirolimus 18-27 vascular endothelial growth factor A Homo sapiens 90-96 32692750-0 2020 Retraction: Rapamycin Inhibits Proliferation of Hemangioma Endothelial Cells by Reducing HIF-1-Dependent Expression of VEGF. Sirolimus 12-21 vascular endothelial growth factor A Homo sapiens 119-123 31354297-0 2019 Rapamycin suppresses angiogenesis and lymphangiogenesis in melanoma by downregulating VEGF-A/VEGFR-2 and VEGF-C/VEGFR-3 expression. Sirolimus 0-9 vascular endothelial growth factor A Homo sapiens 86-92 31354297-12 2019 Conclusion: In conclusion, rapamycin suppresses angiogenesis and lymphangiogenesis in melanoma by blocking the mTOR signal pathway and subsequently downregulating the expression of VEGF-A/VEGFR-2 and VEGF-C/VEGFR-3. Sirolimus 27-36 vascular endothelial growth factor A Homo sapiens 181-187 30846465-9 2019 Baseline serum vascular endothelial growth factor (VEGF)-D >600 pg mL-1 identified subgroups of patients who were more likely to decline on placebo and respond to treatment with sirolimus. Sirolimus 181-190 vascular endothelial growth factor A Homo sapiens 51-55 30186415-10 2018 In addition, rapamycin downregulated the expression of vascular endothelial growth factor (VEGF), matrix metalloproteinase (MMP)-2 and MMP-9 in HUVECs. Sirolimus 13-22 vascular endothelial growth factor A Homo sapiens 55-89 30186415-10 2018 In addition, rapamycin downregulated the expression of vascular endothelial growth factor (VEGF), matrix metalloproteinase (MMP)-2 and MMP-9 in HUVECs. Sirolimus 13-22 vascular endothelial growth factor A Homo sapiens 91-95 29670840-2 2018 Metformin and rapamycin may decrease the expression of VEGF protein and subsequently angiogenesis. Sirolimus 14-23 vascular endothelial growth factor A Homo sapiens 55-59 29670840-10 2018 Rapamycin but not metformin decreases VEGF gene expression in HepG2 cells. Sirolimus 0-9 vascular endothelial growth factor A Homo sapiens 38-42 24451985-9 2014 Furthermore, VEGF significantly stimulated proliferation and migration of pTr cells, but these effects were blocked by SB203580, U0126, rapamycin, and LY294002, which inhibit p38 MAPK, ERK1/2, mTOR, and PI3K, respectively. Sirolimus 136-145 vascular endothelial growth factor A Homo sapiens 13-17 28963126-8 2017 EGF stimulation of p70S6K was also independent of p-AKT Inhibition of the mTORC1 pathway with rapamycin abolished phosphorylation of p70S6K but had no effect on VEGF-A secretion, indicating that EGF-stimulated VEGF-A secretion did not require mTORC1 pathway activation. Sirolimus 94-103 vascular endothelial growth factor A Homo sapiens 210-216 27103123-1 2016 PURPOSE: Sirolimus, an oral mTOR inhibitor, may complement the anti-angiogenic and anti-tumor activity of sunitinib, an oral small molecule inhibitor of multiple receptor tyrosine kinases, by vertical disruption of vascular epithelial growth factor receptor (VEGFR) signaling, by reducing the compensatory production of VEGF in sunitinib-treated patients and also by directly inhibiting tumor cell proliferation. Sirolimus 9-18 vascular endothelial growth factor A Homo sapiens 259-263 27103123-17 2016 4 mg weekly sirolimus did not reduce the sunitinib-induced circulating VEGF production but stimulated more VEGF production through some unknown compensatory mechanism. Sirolimus 12-21 vascular endothelial growth factor A Homo sapiens 107-111 25988388-5 2015 The suppression of HIF-1alpha and VEGF by rapamycin was associated with dephosphorylation of mTOR and the downstream effector ribosomal protein S6 kinase (P70S6K) and 4E-binding protein-1 (4E-BP1) of mTORC1. Sirolimus 42-51 vascular endothelial growth factor A Homo sapiens 34-38 24882386-6 2015 Under basal conditions, mammalian target of rapamycin (mTOR) inhibitors (sirolimus and everolimus) had the most potent anti-inflammatory effect, decreasing both IL-8 release ( -80%) and vascular endothelial growth factor (VEGF) release ( -65%) and preserving the release of the anti-inflammatory cytokine interleukin-1 receptor antagonist (IL-1RA). Sirolimus 73-82 vascular endothelial growth factor A Homo sapiens 186-220 24882386-6 2015 Under basal conditions, mammalian target of rapamycin (mTOR) inhibitors (sirolimus and everolimus) had the most potent anti-inflammatory effect, decreasing both IL-8 release ( -80%) and vascular endothelial growth factor (VEGF) release ( -65%) and preserving the release of the anti-inflammatory cytokine interleukin-1 receptor antagonist (IL-1RA). Sirolimus 73-82 vascular endothelial growth factor A Homo sapiens 222-226 26427711-5 2016 Rapamycin reduced the VEGF expression in the culture medium of MCF-7, while rapamycin did not contribute VEGF expression in the culture medium of HT-29. Sirolimus 0-9 vascular endothelial growth factor A Homo sapiens 22-26 26427711-6 2016 VEGF stimulated cell viability and VEGF inhibition reduced cell viability of MCF-7, and rapamycin dose-dependently restored the cell viability of MCF-7 reduced by rapamycin. Sirolimus 163-172 vascular endothelial growth factor A Homo sapiens 0-4 26382207-0 2015 Retraction: "Rapamycin Attenuates Liver Graft Injury in Cirrhotic Recipient-The Significance of Down-Regulation of Rho-ROCK-VEGF Pathway" by K. Man, M. Su, K.T. Sirolimus 13-22 vascular endothelial growth factor A Homo sapiens 124-128 22117756-11 2012 In primary mesothelial cell culture, rapamycin had no effect on TGFbeta-induced vascular endothelial growth factor (VEGF) but did suppress hypoxia-induced VEGF. Sirolimus 37-46 vascular endothelial growth factor A Homo sapiens 155-159 24018642-7 2014 Furthermore, sunitinib and rapamycin displayed synergistic activity against tube formation by human microvessel endothelial cells as well as outgrowth of endothelial tubes and microvessels both in vitro and in vivo, which is associated with down-regulation of VEGF secretion and HIF1alpha expression. Sirolimus 27-36 vascular endothelial growth factor A Homo sapiens 260-264 23403511-9 2013 Under hypoxia, rapamycin effectively prevented the hypoxia-induced increase of pCREB, Bcl-2, and VEGF-A. Sirolimus 15-24 vascular endothelial growth factor A Homo sapiens 97-103 22419707-14 2012 CONCLUSION: Our findings provide strong evidence for a direct effect of TSH on angiogenesis through its receptor, via cAMP-mammalian target of rapamycin signaling and indicate that this effect is VEGF dependent. Sirolimus 143-152 vascular endothelial growth factor A Homo sapiens 196-200 22900063-0 2012 Rapamycin inhibits proliferation of hemangioma endothelial cells by reducing HIF-1-dependent expression of VEGF. Sirolimus 0-9 vascular endothelial growth factor A Homo sapiens 107-111 21617191-0 2012 Sirolimus-based regimen is associated with decreased expression of glomerular vascular endothelial growth factor. Sirolimus 0-9 vascular endothelial growth factor A Homo sapiens 78-112 23209838-5 2012 Pretreatment with PI3K inhibitor (Ly294002), Akt inhibitor, or mTORC1 inhibitor (rapamycin) blocked the HGF-induced VEGF-A production. Sirolimus 81-90 vascular endothelial growth factor A Homo sapiens 116-122 22900063-3 2012 Here we show that elevated VEGF levels produced by hemangioma endothelial cells are reduced by the mTOR inhibitor rapamycin. Sirolimus 114-123 vascular endothelial growth factor A Homo sapiens 27-31 21964931-9 2011 The use of small molecule inhibitors LY294002 or rapamycin to inhibit PI3K/Akt and p70(S6K) activities, respectively, resulted in diminished HIF-1alpha activation and subsequent VEGF expression. Sirolimus 49-58 vascular endothelial growth factor A Homo sapiens 178-182 20207175-9 2012 In vitro, rapamycin also inhibited the cell proliferation, migration, and invasion, as well as the protein expression of vascular endothelial growth factor-A of T24 urothelial carcinoma cells, whereas rapamycin did not induce significant apoptosis in T24 cells. Sirolimus 10-19 vascular endothelial growth factor A Homo sapiens 121-157 22027770-6 2011 Treatment with 20 ng/ml VEGF obviously promoted MSC proliferation, and this effect was inhibited partially by p38 mitogen-activated protein kinase (MAPK) inhibitor rapamycin, PD98059, SB203580, Go6976, and straurosporine. Sirolimus 164-173 vascular endothelial growth factor A Homo sapiens 24-28 21380626-1 2011 Experimental findings indicate that sirolimus (SRL) inhibits longitudinal growth by mechanisms potentially related to its inhibitory effects on both cell proliferation and expression of vascular endothelial growth factor (VEGF). Sirolimus 36-45 vascular endothelial growth factor A Homo sapiens 186-220 21252047-6 2011 In the presence of rapamycin, a specific mTOR inhibitor, leptin and PDGF were no longer able to activate mTOR, and expression of VEGF was reduced, whereas HIF-1alpha abundance was not affected. Sirolimus 19-28 vascular endothelial growth factor A Homo sapiens 129-133 21380626-1 2011 Experimental findings indicate that sirolimus (SRL) inhibits longitudinal growth by mechanisms potentially related to its inhibitory effects on both cell proliferation and expression of vascular endothelial growth factor (VEGF). Sirolimus 36-45 vascular endothelial growth factor A Homo sapiens 222-226 21363918-6 2011 In contrast, rapamycin exerted less effect on tumoral production of VEGF. Sirolimus 13-22 vascular endothelial growth factor A Homo sapiens 68-72 21189444-8 2010 Additionally, VEGF was significantly suppressed in all individuals after treatment with rapamycin except those who had AA -1154/CA -2578 and AA -1154/AA -2578 VEGF genotype combinations. Sirolimus 88-97 vascular endothelial growth factor A Homo sapiens 14-18 21189444-11 2010 Therefore with regard to our results, different suppressive effect of mycophenolic acid and rapamycin on VEGF production might also be dependent on VEGF genotype. Sirolimus 92-101 vascular endothelial growth factor A Homo sapiens 105-109 21189444-11 2010 Therefore with regard to our results, different suppressive effect of mycophenolic acid and rapamycin on VEGF production might also be dependent on VEGF genotype. Sirolimus 92-101 vascular endothelial growth factor A Homo sapiens 148-152 20922700-16 2010 Sirolimus inhibits not only cell proliferation but also tumor neovascularization by reducing VEGF production and inhibiting VEGF receptor signaling in endothelial cells. Sirolimus 0-9 vascular endothelial growth factor A Homo sapiens 93-97 20922700-16 2010 Sirolimus inhibits not only cell proliferation but also tumor neovascularization by reducing VEGF production and inhibiting VEGF receptor signaling in endothelial cells. Sirolimus 0-9 vascular endothelial growth factor A Homo sapiens 124-128